Risk-based prostate cancer screening: Who and how?

Current Urology Reports

Volumn 14, Issue 3, 2013, Pages 192-198

  Glass, Allison S ^a   Cary, K Clint ^a   Cooperberg, Matthew R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical risk; Prostate cancer; Prostate specific antigen; Risk based; Screening tools

Indexed keywords

BIOLOGICAL MARKER; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

AGE DISTRIBUTION; ARTICLE; CANCER RISK; CANCER SCREENING; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; DIGITAL RECTAL EXAMINATION; DNA FINGERPRINTING; ENVIRONMENTAL EXPOSURE; ETHNIC DIFFERENCE; FAMILY HISTORY; FUTUROLOGY; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; TRANSRECTAL ULTRASONOGRAPHY;

ADENOCARCINOMA; AGE FACTORS; EARLY DETECTION OF CANCER; HUMANS; KALLIKREINS; MALE; MASS SCREENING; PATIENT SELECTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 84878701520     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-013-0319-8     Document Type: Article

References (89)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Surveillance, epidemiology and end results. Seer prostate cancer data. Available at http://www.Seer.Cancer.Gov/. Accessed January 2013.
3. Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, et al. Quantifying the role of PSA screening in the us prostate cancer mortality decline. Cancer Causes Control. 2008;19:175-81.
4. •• Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF, Heijnsdijk EA, et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer. 2012;118:5955-63. An outstanding rebuttal to the common claim that mortality declines in prostate cancer can be attributed primarily to improvements in treatment.
5. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007;178:S14-9.
6. • Andriole GL, Crawford ED, Grubb III RL, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125-32. Important update to the PLCO trial, acknowledging that the trial was a randomization between opportunitstic and annual screening, not between screening and no-screening.
7. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-8.
8. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981-90.
9. •• Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the gotebörg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11:725-32. The best randomized screening trial reported to date: Men were younger at diagnosis than PLCO or ERSPC, had less contamination in the control arm, and - most importantly - were not uniformly treated for low-risk disease.
10. Schroder FH, Hugosson J, Carlsson S, Tammela T, Maattanen L, Auvinen A, et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European randomized study of screening for prostate cancer (erspc). Eur Urol. 2012;62:745-52.
11. • Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C. Assessing contamination and compliance in the prostate component of the prostate, lung, colorectal, and ovarian (plco) cancer screening trial. Clin Trials. 2010;7:303-11. Important paper reporting the true PSA contamination rate in the PLCO trial: 79 % of "control" patients had some exposure to PSA testing.
12. Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA. 2006;296:2336-42.
13. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009;182:2232-41.
14. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. Eau guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61-71.
15. Kawachi MH, Bahnson RR, Barry M, Busby JE, Carroll PR, Carter HB, et al. Nccn clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Cancer Netw JNCCN. 2010;8:240-62.
16. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, et al. American cancer society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60:70-98.
17. • Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol. 2011;29:235-41. An observational study demonstrating that treatment decisions are guided too heavily by age and not enough by disease risk.
18. Schwartz KL, Alibhai SM, Tomlinson G, Naglie G, Krahn MD. Continued undertreatment of older men with localized prostate cancer. Urology. 2003;62:860-5.
19. Stangelberger A, Waldert M, Djavan B. Prostate cancer in elderly men. Rev Urol. 2008;10:111-9.
20. Stricker PD, Frydenberg M, Kneebone A, Chopra S. Informed prostate cancer risk-adjusted testing: a new paradigm. BJU Int. 2012;110 Suppl 4:30-4.
21. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, et al. Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst. 2006;98:529-34.
22. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
23. Hsieh K, Albertsen PC. Populations at high risk for prostate cancer. Urol Clin N Am. 2003;30:669-76.
24. Shao YH, Demissie K, Shih W, Mehta AR, Stein MN, Roberts CB, et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst. 2009;101:1280-3.
25. • Porten SP, Richardson DA, Odisho AY, McAninch JW, Carroll PR, Cooperberg MR. Disproportionate presentation of high risk prostate cancer in a safety net health system. J Urol. 2010;184:1931-6. The greatest needs in earlier detection and better treatment for prostate cancer are in low-socioeconomic- status men. The reasons are likely multifactorial.
26. Mokete M, Shackley DC, Betts CD, O'Flynn KJ, Clarke NW. The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the uk. BJU Int. 2006;97:266-9.
27. Miller DC, Litwin MS, Bergman J, Stepanian S, Connor SE, Kwan L, et al. Prostate cancer severity among low income, uninsured men. J Urol. 2009;181:579-83. discussion 583-574.
28. Dale W, Vijayakumar S, Lawlor EF, Merrell K. Prostate cancer, race, and socioeconomic status: inadequate adjustment for social factors in assessing racial differences. Prostate. 1996;29:271-81.
29. Gilligan T, Wang PS, Levin R, Kantoff PW, Avorn J. Racial differences in screening for prostate cancer in the elderly. Arch Intern Med. 2004;164:1858-64.
30. Miller DC, Gelberg L, Kwan L, Stepanian S, Fink A, Andersen RM, et al. Racial disparities in access to care for men in a public assistance program for prostate cancer. J Community Health. 2008;33:318-35.
31. Brandt A, Bermejo JL, Sundquist J, Hemminki K. Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members. Eur Urol. 2010;58:275-80.
32. van Roermund JG, Witjes JA. The impact of obesity on prostate cancer. World J Urol. 2007;25:491-7.
33. Smith MR, Bae K, Efstathiou JA, Hanks GE, Pilepich MV, Sandler HM, et al. Diabetes and mortality in men with locally advanced prostate cancer: Rtog 92-02. J Clin Oncol. 2008;26:4333-9.
34. Wu C, Moreira DM, Gerber L, Rittmaster RS, Andriole GL, Freedland SJ. Diabetes and prostate cancer risk in the reduce trial. Prostate Cancer Prostatic Dis. 2011;14:326-31.
35. Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI. Components of the metabolic syndrome and risk of prostate cancer: the hunt 2 cohort, Norway. Cancer Causes Control: CCC. 2009;20:1181-92.
36. Mydlo JH, Tieng NL, Volpe MA, Chaiken R, Kral JG. A pilot study analyzing PSA, serum testosterone, lipid profile, body mass index and race in a small sample of patients with and without carcinoma of the prostate. Prostate Cancer Prostatic Dis. 2001;4:101-5.
37. Antonelli JA, Jones LW, Banez LL, Thomas JA, Anderson K, Taylor LA, et al. Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy. J Urol. 2009;182:2226-31.
38. Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E. Smoking and prostate cancer survival and recurrence. JAMA. 2011;305:2548-55.
39. Walsh TJ, Schembri M, Turek PJ, Chan JM, Carroll PR, Smith JF, et al. Increased risk of high-grade prostate cancer among infertile men. Cancer. 2010;116:2140-7.
40. • Daskivich TJ, Chamie K, Kwan L, Labo J, Dash A, Greenfield S, et al. Comorbidity and competing risks for mortality in men with prostate cancer. Cancer. 2011;117:4642-50. An important study reinforcing that most men diagnosed with low-risk prostate cancer die of other causes.
41. • Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol. 2011;29:1335-41. Like Daskivich et al., a strong argument for screening decisions based on comorbidity and life expectancy, rather than chronological age alone.
42. Schroder FH, Roobol MJ, Andriole GL, Fleshner N. Defining increased future risk for prostate cancer: evidence from a population based screening cohort. J Urol. 2009;181:69-74. discussion 74.
43. Fleshner NE, Lawrentschuk N. Risk of developing prostate cancer in the future: overview of prognostic biomarkers. Urology. 2009;73:S21-7.
44. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-61.
45. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997;277:1452-5.
46. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005;294:66-70.
47. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995;273:289-94.
48. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore longitudinal study of aging. Urology. 2001;58:411-6.
49. Antenor JA, Han M, Roehl KA, Nadler RB, Catalona WJ. Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J Urol. 2004;172:90-3.
50. Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology. 2006;67:316-20.
51. •• Vickers AJ, Cronin AM, Bjork T, Manjer J, Nilsson PM, Dahlin A, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ. 2010;341:c4521. A unique cohort, analysis of which demonstrates one component of what a "smarter screening" program may look like.
52. Roobol MJ, Roobol DW, Schroder FH. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/ml or less in a population-based screening setting? (erspc, section rotterdam). Urology. 2005;65:343-6.
53. Carter HB, Pearson JD, Waclawiw Z, Metter EJ, Chan DW, Guess HA, et al. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology. 1995;45:591-6.
54. Loeb S, Roehl KA, Helfand BT, Kan D, Catalona WJ. Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection? J Urol. 2010;183:112-6.
55. Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst. 2006;98:1521-7.
56. Ulmert D, Serio AM, O'Brien MF, Becker C, Eastham JA, Scardino PT, et al. Long-term prediction of prostate cancer: Prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol. 2008;26:835-41.
57. Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst. 2011;103:462-9.
58. Okotie OT, Roehl KA, Han M, Loeb S, Gashti SN, Catalona WJ. Characteristics of prostate cancer detected by digital rectal examination only. Urology. 2007;70:1117-20.
59. Panebianco V, Sciarra A, Marcantonio A, Forte V, Biondi T, Laghi A, et al. Conventional imaging and multiparametric magnetic resonance (mri, mrs, dwi, mrp) in the diagnosis of prostate cancer. Q J Nucl Med Mol Imaging. 2012;56:331-42.
60. Chun FK, Karakiewicz PI, Briganti A, Gallina A, Kattan MW, Montorsi F, et al. Prostate cancer nomograms: an update. Eur Urol. 2006;50:914-26. discussion 926.
61. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004;350:2239-46.
62. Parekh DJ, Ankerst DP, Higgins BA, Hernandez J, Canby-Hagino E, Brand T, et al. External validation of the prostate cancer prevention trial risk calculator in a screened population. Urology. 2006;68:1152-5.
63. Eyre SJ, Ankerst DP, Wei JT, Nair PV, Regan MM, Bueti G, et al. Validation in a multiple urology practice cohort of the prostate cancer prevention trial calculator for predicting prostate cancer detection. J Urol. 2009;182:2653-8.
64. Hernandez DJ, Han M, Humphreys EB, Mangold LA, Taneja SS, Childs SJ, et al. Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone. BJU Int. 2009;103:609-14.
65. • Nam RK, Kattan MW, Chin JL, Trachtenberg J, Singal R, Rendon R, et al. Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol. 2011;29:2959-64. Excellent analysis of risk calculators to be used to help decide whether to proceed with biopsy.
66. Roobol MJ, Steyerberg EW, Kranse R, Wolters T, van den Bergh RC, Bangma CH, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol. 2010;57:79-85.
67. van Vugt HA, Roobol MJ, Kranse R, Maattanen L, Finne P, Hugosson J, et al. Prediction of prostate cancer in unscreened men: external validation of a risk calculator. Eur J Cancer. 2011;47:903-9.
68. Trottier G, Roobol MJ, Lawrentschuk N, Bostrom PJ, Fernandes KA, Finelli A, et al. Comparison of risk calculators from the prostate cancer prevention trial and the European randomized study of screening for prostate cancer in a contemporary Canadian cohort. BJU Int. 2011;108:E237-44.
69. Oliveira M, Marques V, Carvalho AP, Santos A. Head-to-head comparison of two online nomograms for prostate biopsy outcome prediction. BJU Int. 2011;107:1780-3.
70. Cavadas V, Osorio L, Sabell F, Teves F, Branco F, Silva-Ramos M. Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort. Eur Urol. 2010;58:551-8.
71. Nam RK, Toi A, Klotz LH, Trachtenberg J, Jewett MA, Appu S, et al. Assessing individual risk for prostate cancer. J Clin Oncol. 2007;25:3582-8.
72. Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, et al. Accuracy of pca3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol. 2010;183:534-8.
73. Ankerst DP, Groskopf J, Day JR, Blase A, Rittenhouse H, Pollock BH, et al. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol. 2008;180:1303-8. discussion 1308.
74. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8:497-511.
75. Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, et al. Frequency of the tmprss2:Erg gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol. 2007;60:1238-43.
76. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, et al. Duplication of the fusion of tmprss2 to erg sequences identifies fatal human prostate cancer. Oncogene. 2008;27:253-63.
77. Nam RK, Sugar L, Wang Z, Yang W, Kitching R, Klotz LH, et al. Expression of tmprss2:Erg gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther. 2007;6:40-5.
78. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, et al. Tmprss2:Erg fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006;66:8337-41.
79. Rubio-Briones J, Fernandez-Serra A, Calatrava A, Garcia-Casado Z, Rubio L, Bonillo MA, et al. Clinical implications of tmprss2-erg gene fusion expression in patients with prostate cancer treated with radical prostatectomy. J Urol. 2010;183:2054-61.
80. Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, et al. A prospective, multicenter, national cancer institute early detection research network study of [-2]propsa: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev. 2010;19:1193-200.
81. Vickers AJ, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European randomized study of prostate cancer screening in Goteborg, Sweden. BMC Med. 2008;6:19.
82. Vickers A, Cronin A, Roobol M, Savage C, Peltola M, Pettersson K, et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol. 2010;28:2493-8.
83. Kim ST, Cheng Y, Hsu FC, Jin T, Kader AK, Zheng SL, et al. Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic variation. Prostate. 2010;70:1729-38.
84. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. Germline mutations in hoxb13 and prostate-cancer risk. N Engl J Med. 2012;366:141-9.
85. Langer DL, van der Kwast TH, Evans AJ, Trachtenberg J, Wilson BC, Haider MA. Prostate cancer detection with multi-parametric mri: logistic regression analysis of quantitative t2, diffusion-weighted imaging, and dynamic contrast-enhanced mri. J Magn Reson Imaging: JMRI. 2009;30:327-34.
86. Hambrock T, Somford DM, Huisman HJ, van Oort IM, Witjes JA, Hulsbergen-van de Kaa CA, et al. Relationship between apparent diffusion coefficients at 3.0-t mr imaging and gleason grade in peripheral zone prostate cancer. Radiology. 2011;259:453-61.
87. Villeirs GM, De Meerleer GO, De Visschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients. Eur J Radiol. 2011;77:340-5.
88. Yoshizako T, Wada A, Hayashi T, Uchida K, Sumura M, Uchida N, et al. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer. Acta Radiol. 2008;49:1207-13.
89. Delongchamps NB, Beuvon F, Eiss D, Flam T, Muradyan N, Zerbib M, et al. Multiparametric mri is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer. Prostate Cancer Prostatic Dis. 2011;14:232-7.